Strides has announced that its step-down wholly-owned subsidiary, Vensun Pharmaceuticals, Inc USA and its partner Pharmaceutics International, Inc (Pii) have received approval for jointly developed Potassium Chloride Extended-Release tablets USP, 10 mEq (750 mg), 15 mEq (1,125 mg), and 20 mEq (1,500 mg) product from the United States Food & Drug Administration (US FDA). The product is an immediately dispersing extended-release oral dosage form of potassium chloride and is a generic version of Potassium Chloride Extended-Release tablets of Merck, Inc.
